These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 6320923)

  • 1. Subcortical limbic 3H-N-propylnorapomorphine binding sites are markedly modulated by cholecystokinin-8 in vitro.
    Agnati LF; Fuxe K
    Biosci Rep; 1983 Dec; 3(12):1101-5. PubMed ID: 6320923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for cholecystokinin-dopamine receptor interactions in the central nervous system of the adult and old rat. Studies on their functional meaning.
    Agnati LF; Fuxe K; Giardino L; Calza L; Zoli M; Battistini N; Benfenati F; Vanderhaeghen JJ; Guidolin D; Ruggeri M
    Ann N Y Acad Sci; 1985; 448():315-33. PubMed ID: 2862827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides.
    Fuxe K; Agnati LF; Köhler C; Kuonen D; Ogren SO; Andersson K; Hökfelt T
    J Neural Transm; 1981; 51(1-2):3-37. PubMed ID: 7264628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholecystokinin octapeptide in vitro and ex vivo strongly modulates striatal dopamine D2 receptors in rat forebrain sections.
    Li XM; Hedlund PB; Fuxe K
    Eur J Neurosci; 1995 May; 7(5):962-71. PubMed ID: 7613631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for the existence of receptor--receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides.
    Fuxe K; Agnati LF; Benfenati F; Celani M; Zini I; Zoli M; Mutt V
    J Neural Transm Suppl; 1983; 18():165-79. PubMed ID: 6192208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholecystokinin peptides in vitro modulate the characteristics of the striatal 3H-N-propylnorapomorphine sites.
    Agnati LF; Celani MF; Fuxe K
    Acta Physiol Scand; 1983 May; 118(1):79-81. PubMed ID: 6312748
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological and mechanistic studies of cholecystokinin-facilitated [3H]dopamine efflux from rat nucleus accumbens.
    Vickroy TW; Bianchi BR
    Neuropeptides; 1989 Jan; 13(1):43-50. PubMed ID: 2466220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct properties of cholecystokinin-8 and mixed dopamine-cholecystokinin-8 neurons innervating the nucleus accumbens.
    Studler JM; Reibaud M; Tramu G; Blanc G; Glowinski J; Tassin JP
    Ann N Y Acad Sci; 1985; 448():306-14. PubMed ID: 3861123
    [No Abstract]   [Full Text] [Related]  

  • 9. In vivo electrochemical analysis of cholecystokinin-induced inhibition of dopamine release in the nucleus accumbens.
    Lane RF; Blaha CD; Phillips AG
    Brain Res; 1986 Nov; 397(1):200-4. PubMed ID: 3801862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine receptors and ergot drugs. Evidence that an ergolene derivative is a differential agonist at subcortical limbic dopamine receptors.
    Fuxe K; Fredholm BB; Agnati LF; Corrodi H
    Brain Res; 1978 May; 146(2):295-311. PubMed ID: 647392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of cholecystokinin on the in vivo release of newly synthesized [3H]dopamine from the nucleus accumbens of the rat.
    Voigt MM; Wang RY; Westfall TC
    J Neurosci; 1985 Oct; 5(10):2744-9. PubMed ID: 4045551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of dopamine D2 receptor affinity by cholecystokinin octapeptide in fibroblast cells cotransfected with human CCKB and D2L receptor cDNAs.
    Dasgupta S; Li XM; Jansson A; Finnman UB; Matsui T; Rinken A; Arenas E; Agnati LF; Fuxe K
    Brain Res Mol Brain Res; 1996 Mar; 36(2):292-9. PubMed ID: 8965650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat.
    Crawley JN; Hommer DW; Skirboll LR
    Brain Res; 1985 Jun; 335(2):337-41. PubMed ID: 4005562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of isomers of apomorphines on dopamine receptors in striatal and limbic tissue of rat brain.
    Kula NS; Baldessarini RJ; Bromley S; Neumeyer JL
    Life Sci; 1985 Sep; 37(11):1051-7. PubMed ID: 4033350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites.
    Agnati LF; Fuxe K; Benfenati F; Battistini N
    Acta Physiol Scand; 1983 Dec; 119(4):459-61. PubMed ID: 6320589
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of chronic treatment with morphine on the binding of 3H-N-n-propylnorapomorphine to striatal membranes of rats: influence of prolyl-leucyl-glycinamide.
    Das S; Bhargava HN
    Pharmacology; 1985; 31(5):241-7. PubMed ID: 2866551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholecystokinin neuron systems and their interactions with the presynaptic features of the dopamine neuron systems. A morphometric and neurochemical analysis involving studies on the action of cholecystokinin-8 and cholecystokinin-58.
    Fuxe K; Agnati LF; Vanderhaeghen JJ; Tatemoto K; Andersson K; Eneroth P; Härfstrand A; Von Euler G; Toni R; Goldstein M
    Ann N Y Acad Sci; 1985; 448():231-54. PubMed ID: 2862825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic properties of the in vivo accumulation of 3H-(-)-N-n-propylnorapomorphine in mouse brain.
    Ross SB; Jackson DM
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Jul; 340(1):13-20. PubMed ID: 2571943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible involvement of G-proteins in the regulation of striatal dopamine D2 receptor affinity by cholecystokinin octapeptide.
    Li XM; Jansson A; Finnman UB; Agnati LF; Fuxe K
    Neurosci Lett; 1997 Jun; 228(3):171-4. PubMed ID: 9218635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.